Clinical Profile, Treatment and Survival Outcome of Testicular Tumors: A Pakistani Perspective |
Bhatti, Abu Bakar Hafeez
(Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre)
Ahmed, Irfan (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) Ghauri, Rashid Khan (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) Saeed, Qamar (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) Mir, Khurram (Department of Surgical Oncology, Shaukat Khanum Memorial Cancer Hospital and Research Centre) |
1 | Gilligan TD, Seidenfeld J, Basch EM, et al (2010). American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol, 28, 3388-404. DOI ScienceOn |
2 | Horwich A, Sleijfer DT, Fossa SD, et al (1997). Randomized trial of bleomycin, etoposide, and cisplatin compared with bleomycin, etoposide, and carboplatin in good-prognosis metastatic nonseminomatous germ cell cancer: a Multi institutional Medical Research Council/European Organization for Research and Treatment of Cancer Trial. J Clin Oncol, 15, 1844-52. |
3 | Klein EA (1993). Tumour markers in testis cancer. Urol Clin North Am, 20, 67-73. |
4 | Kobayashi K, Saito T, Kitamura Y, et al (2013). Oncological outcomes in patients with stage I testicular seminoma and nonseminoma: pathological risk factors for relapse and feasibility of surveillance after orchiectomy. Diagn Pathol, 8, 57. DOI |
5 | Mushtaq S, Jamal S, Mamoon N, Akbar N, Khadim T (2007). The pathological spectrum of malignant testicular tumours in northern Pakistan. J Pak Med Assoc, 57, 499-501. |
6 | Albers P, Albrecht W, Algaba F, et al (2005). Guidelines on testicular cancer. Eur Urol, 48, 885-94. DOI ScienceOn |
7 | Bokemeyer C, Kohrmann O, Tischler J, et al (1996). A randomized trial of cisplatin, etoposide and bleomycin (PEB) versus carboplatin, etoposide and bleomycin (CEB) for patients with 'good-risk' metastatic non-seminomatous germ cell tumors. Ann Oncol, 7, 1015-21. DOI |
8 | Bhutani M, Kumar L, Seth A, et al (2002).Germ cell tumours of the testis: clinical features, treatment outcome and prognostic factors. Natl Med J India, 15, 18-21. |
9 | Biggs ML, Schwartz SM (2004). Differences in testis cancer survival by race and ethnicity: a population-based study, 1973-1999 (United States). Cancer Causes Control, 15, 437-44. DOI |
10 | Bray F, Ferlay J, Devesa SS, McGlynn KA, Moller H (2006). Interpreting the international trends in testicular seminoma and non seminoma incidence. Nat Clin Pract Urol, 3, 532-43. |
11 | Bray F, Richiardi L, Ekbom A, et al (2006). Do testicular seminoma and nonseminoma share the same etiology? Evidence from an age period-cohort analysis of incidence trends in eight European countries. Cancer Epidemiol Biomarkers Prev, 15, 652-8. DOI |
12 | Beard CJ, Travis LB, Chen MH, et al (2013). Outcomes in stage I testicular seminoma: a population-based study of 9193 patients. Cancer, 119, 2771-7. DOI |
13 | Tan GH, Azrif M, Shamsul AS, et al (2011). Clinicopathological features and survival of testicular tumours in a Southeast Asian university hospital: a ten-year review. Asian Pac J Cancer Prev, 12, 2727-30. |
14 | Travis LB, Fossa SD, Schonfeld SJ, et al (2005). Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst, 97, 1354-65. DOI ScienceOn |
15 | Stang A, Rusner C, Eisinger B, Stegmaier C, Kaatsch P (2009). Subtype specific incidence of testicular cancer in Germany: a pooled analysis of nine population-based cancer registries. Int J Androl, 32, 306-16. DOI ScienceOn |
16 | Shin YS, Kim HJ (2013).Current management of testicular cancer. Korean J Urol, 54, 2-10. DOI ScienceOn |
17 | Van den Belt-Dusebout AW, de Wit R, Gietema JA, et al (2007). Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol, 25, 4370-8. DOI ScienceOn |
18 | Wanderas EH, Tretli S, Fossa SD (1995). Trends in incidence of testicular cancer in Norway 1955-1992. Eur J Cancer, 31, 2044-8. DOI ScienceOn |
19 | Ward KD, Vander Weg MW, Read MC, Sell MA, Beech BM (2005). Testicular cancer awareness and self-examination among adolescent males in a community-based youth organization. Prev Med, 41, 386-98. DOI ScienceOn |
20 | Walschaerts M, Huyghe E, Muller A, et al (2008). Doubling of testicular cancer incidence rate over the last 20 years in southern France. Cancer Causes Control, 19, 155-61. DOI |
21 | Ondrus D, Hornak M, Matoska J, Kausitz J, Belan V (1992). Primary chemotherapy in the management of low stage (IIA and IIB) non-seminomatous germ cell testicular tumours. Int Urol Nephrol, 24, 299-304. DOI |
22 | Zagars GK, Ballo MT, Lee AK, Strom SS (2004). Mortality after cure of testicular seminoma. J Clin Oncol, 22, 640-7. DOI ScienceOn |
23 | Purdue MP, Devesa SS, Sigurdson AJ, McGlynn KA (2005). International patterns and trends in testis cancer incidence. Int J Cancer, 115, 822-7. DOI ScienceOn |
24 | Nguyen MM, Ellison LM (2005). Testicular cancer patterns in Asian-American males: an opportunity for public health education to impact outcomes. Urol, 66, 606-9. DOI ScienceOn |
25 | Pont J, Albrecht W, Postner G, et al (1996). Adjuvant chemotherapy for high-risk clinical stage I nonseminomatous testicular germ cell cancer: long-term results of a prospective trial. J Clin Oncol, 14, 441-8. |
26 | Shah MN, Devesa SS, Zhu K, McGlynn KA (2007). Trends in testicular germ cell tumours by ethnic group in the United States. Int J Androl, 30, 206-13. DOI ScienceOn |
27 | Franks P, Fiscella, K, Meldrum S (2005). Racial disparities in the content of primary care office visits. J Gen Intern Med, 20, 599-603. DOI |
28 | Chia VM, Quraishi SM, Devesa SS, et al (2010). International trends in the incidence of testicular cancer, 1973-2002. Cancer Epidemiol Biomarkers Prev, 19, 1151-9. DOI ScienceOn |
29 | Einhorn LH, Williams SD, Loehrer PJ, et al (1989). Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol. J Clin Oncol, 7, 387-91. |
30 | Sataa S, Nfoussi H, Abaza H, et al (2012). Testicular cancer patterns in Tunisian men: diagnosis problems, pathological types and prognosis. About 41 patients. Tunis Med, 90, 613-8. |
31 | Cost NG (2013). Testicular germ cell tumors Current concepts and management strategies. Minerva Urol Nefrol, 65, 133-55. |
![]() |